{
 "id": "mantle-cell-lymphoma",
 "name": "Mantle Cell Lymphoma",
 "aliases": [
  "Mantle cell lymphoma (MCL)"
 ],
 "acronyms": [
  "MCL"
 ],
 "bodySystem": "cancer",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 2,
  "limited": 0,
  "waitlist": 0,
  "closed": 0
 },
 "funds": [
  {
   "fund": "Mantle Cell Lymphoma",
   "organization": "HealthWell Foundation",
   "status": "open",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Open.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Mantle cell lymphoma (MCL)",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "open",
   "dateOnPage": null,
   "awardLevelUsd": 5000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Open.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "ACALABRUTINIB",
   "pages": [
    {
     "brand": "Calquence",
     "url": "https://omnirx.org/negotiated-drugs/calquence"
    }
   ],
   "labelSentence": "In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22dd4835ef-e1bc-4997-a399-1ffa2556fbfe%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 8600,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Lenalidomide",
   "pages": [
    {
     "brand": "Revlimid",
     "url": "https://omnirx.org/medicines/revlimid"
    }
   ],
   "labelSentence": "Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%225fa97bf5-28a2-48f1-8955-f56012d296be%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "BMS Access Support",
     "url": "https://omnirx.org/assistance/bms-access-support-eliquis",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Cancer Drug Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/cancer-drug-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Bristol Myers Squibb Patient Assistance Foundation",
     "url": "https://www.bmspaf.org/#/medicines",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": "additional REMS requirements",
     "listKind": "Medicines available through the Foundation",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Pirtobrutinib",
   "pages": [
    {
     "brand": "Jaypirca",
     "url": "https://omnirx.org/medicines/jaypirca"
    }
   ],
   "labelSentence": "Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22bd551845-0878-49a4-860f-839b83f6b801%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Lilly Cares Foundation Patient Assistance Program",
     "url": "https://omnirx.org/assistance/lilly-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available Medications: list of all products",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Zanubrutinib",
   "pages": [
    {
     "brand": "Brukinsa",
     "url": "https://omnirx.org/medicines/brukinsa"
    }
   ],
   "labelSentence": "Mantle cell lymphoma (MCL) who have received at least one prior therapy.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%223e08fe23-d70e-424c-bc51-1222e320f902%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [
  {
   "fund": "American Cancer Society Cancer Care Continuity Fund",
   "organization": "Patient Advocate Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.patientadvocate.org/connect-with-services/financial-aid-funds/"
  },
  {
   "need": "testing",
   "fund": "Cancer genetic and genomic testing",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "need": "home care",
   "fund": "Cancer Home Care Services",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "behavioral health",
   "fund": "Cancer-Related Behavioral Health",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "pain management",
   "fund": "Cancer-Related Pain Management",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare CAR-T Caregiver Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare Caregiver Financial Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "clinical trial costs",
   "fund": "CancerCare Clinical Trial Financial Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "transportation",
   "fund": "CancerCare Gets You There - Transportation Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "behavioral health",
   "fund": "Oncology Caregiver Behavioral Health Fund (Accepting phone applications only)",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  }
 ],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}